Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IRONWOOD PHARMACEUTICALS, INC.

(IRWD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ironwood appoints Sarissa's Denner to board; shares surge

11/06/2020 | 12:58pm EST

BOSTON, Nov 6 (Reuters) - Ironwood Pharmaceuticals on Friday handed a board seat to Sarissa Capital Management, sparking its shares to surge as much as 14% when the activist investor secured the spot after a quiet but forceful 2-1/2-year campaign to join the group.

Alexander Denner, a widely known healthcare investor who founded Sarissa in 2013, will join Ironwood's board as its 10th director, the company said.

"His wealth of knowledge will be invaluable as we continue on our mission to advance GI (gastrointestinal) medicines, redefine the standard of care for GI patients, and deliver shareholder value," Julie McHugh, chair of Ironwood's board, said in a statement about Denner.

The company's shares were trading at $10.94, up 9%, at midday.

Ever since Sarissa, which owned 14 million shares, or roughly 9% of the Boston-based company, at the end of June, bought into Ironwood in late 2017, Denner has wanted a say in shaping its future.

Even though Ironwood's irritable bowel syndrome drug Linzess was widely prescribed, posting U.S. net sales of $803 million in 2019, the share price has languished around $10.

Certain investors grew restless and said they wanted to see a sale of the company to a larger drug company, at a time when Ironwood was already collaborating with Allergan, which was sold to AbbVie in 2020. So far, Sarissa, which has about $1.5 billion in capital, has been publicly mum on exactly what it would like beyond a higher share price.

Denner, who earned a Ph.D. in biomedical engineering from Yale and previously worked for famed investor Carl Icahn, has a reputation in the activist investing world of working collaboratively behind the scenes. He has run only one proxy contest and kept The Medicines Company founder Clive Meanwell as chief innovation officer after he was replaced as CEO.

But Denner also engineered the sales of Ariad Pharmaceuticals to Takeda and Bioverativ to Sanofi. (Reporting by Svea Herbst-Bayliss; Editing by Kirsten Donovan and Paul Simao)


ę Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE INC. 0.55% 115.91 Delayed Quote.8.18%
BB BIOTECH AG 1.65% 79.95 Delayed Quote.7.82%
ICAHN ENTERPRISES L.P. -1.27% 49.91 Delayed Quote.-1.50%
IRONWOOD PHARMACEUTICALS, INC. -1.35% 10.94 Delayed Quote.-3.95%
SANOFI -0.50% 85.47 Real-time Quote.9.07%
All news about IRONWOOD PHARMACEUTICALS, INC.
12/01Ironwood Pharmaceuticals Hires Sravan Emany as Chief Financial Officer
MT
12/01IRONWOOD PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financial Statem..
AQ
12/01Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer
BU
11/05Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an ..
AQ
11/04IRONWOOD PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Conditi..
AQ
11/04Ironwood Pharmaceuticals Q3 Earnings, Revenue Rise
MT
11/04IRONWOOD : Q3 Earnings Snapshot
AQ
11/04Ironwood Pharmaceuticals 3Q 2021 Investor Update Conference Call
PU
11/04Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Deve..
PU
11/04Earnings Flash (IRWD) IRONWOOD PHARMACEUTICALS Posts Q3 EPS $0.33
MT
More news
Analyst Recommendations on IRONWOOD PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 407 M - -
Net income 2021 540 M - -
Net cash 2021 119 M - -
P/E ratio 2021 3,36x
Yield 2021 -
Capitalization 1 790 M 1 790 M -
EV / Sales 2021 4,10x
EV / Sales 2022 3,18x
Nbr of Employees 232
Free-Float 98,6%
Chart IRONWOOD PHARMACEUTICALS, INC.
Duration : Period :
Ironwood Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IRONWOOD PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 10,94 $
Average target price 12,50 $
Spread / Average Target 14,3%
EPS Revisions
Managers and Directors
Thomas A. McCourt President, Chief Executive Officer & Director
Jason Rickard Chief Financial Officer
Julie Harris McHugh Executive Chairman
Michael Shetzline Chief Medical Officer & Senior Vice President
Cristina Almansa Head-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
IRONWOOD PHARMACEUTICALS, INC.-3.95%1 790
MODERNA, INC.197.32%125 937
LONZA GROUP AG28.34%58 955
IQVIA HOLDINGS INC.44.70%49 527
SEAGEN INC.-9.64%28 937
CELLTRION, INC.-41.09%24 625